Peptides Similar to IO102-IO103

Immunotherapies Related to IO102-IO103#

IO102-IO103 occupies a unique position in the cancer immunotherapy landscape as an off-the-shelf dual-peptide vaccine targeting immunosuppressive pathways. The most relevant comparisons are with other cancer vaccine platforms and checkpoint inhibitor combination strategies being developed for melanoma and other solid tumors.

mRNA-4157/V940 (Personalized Neoantigen Vaccine)#

mRNA-4157/V940 (Moderna/Merck) is the most advanced personalized cancer vaccine and the most relevant comparator in the melanoma setting.

Mechanism comparison: mRNA-4157 encodes up to 34 patient-specific tumor neoantigens identified by whole-exome sequencing. IO102-IO103 targets universal immunosuppressive proteins (IDO and PD-L1) present across all patients. The approaches are complementary in principle -- one targets the tumor's unique mutations, the other targets the tumor's universal immune evasion mechanisms.

Clinical data: mRNA-4157 combined with pembrolizumab showed significant improvement in recurrence-free survival in the adjuvant melanoma setting (KEYNOTE-942/V940-001). IO102-IO103 was tested in the first-line metastatic melanoma setting with an 8.4-month PFS improvement.

Nivolumab + Relatlimab (Opdualag)#

Opdualag combines PD-1 blockade (nivolumab) with LAG-3 blockade (relatlimab) and is approved for first-line metastatic melanoma. It represents the dual checkpoint approach.

Key differences: Opdualag blocks two inhibitory checkpoints using monoclonal antibodies. IO102-IO103 activates T cells against immunosuppressive targets using peptide vaccination. The approaches use fundamentally different modalities (antibodies vs vaccine) but address overlapping immunosuppressive pathways.

Clinical data: Opdualag showed median PFS of 10.1 months vs 4.6 months for nivolumab alone (RELATIVITY-047). IO102-IO103 + pembrolizumab showed 19.4 months median PFS in the phase 3 trial, though the comparator arm (pembrolizumab alone, 11.0 months) reflects a different patient population.

Ipilimumab + Nivolumab Combination#

The combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) is a standard first-line option for advanced melanoma with high efficacy but substantial toxicity.

Key differences: Ipi/nivo achieves high response rates and durable survival but with grade 3-4 adverse events in ~60% of patients. IO102-IO103 + pembrolizumab showed no increase in immune-mediated adverse events compared to pembrolizumab alone, representing a significantly more tolerable combination approach.

Other Cancer Vaccine Platforms#

Several other cancer vaccine approaches are in clinical development:

Tumor-infiltrating lymphocyte (TIL) therapy: Lifileucel (Amtagvi) is an adopted cell therapy approved for melanoma. It uses the patient's own tumor-infiltrating lymphocytes expanded ex vivo, representing a fundamentally different approach from vaccination.

Other peptide vaccines: Multiple peptide-based cancer vaccines are in development for various tumor types, but IO102-IO103 is the most advanced in terms of clinical data in melanoma.

DC vaccines: Dendritic cell-based vaccines (e.g., sipuleucel-T for prostate cancer) use autologous dendritic cells loaded with tumor antigens. They are more complex to manufacture than synthetic peptide vaccines.

Summary Comparison#

Related Reading#

• IO102-IO103 overview and research guide
• IO102-IO103 research evidence
• IO102-IO103 dosing protocols